Life Sciences

  • July 17, 2026

    Taylor Farms, Taco Bell Sued Over Cyclospora Outbreak

    Taylor Farms and Taco Bell are facing proposed class litigation in California, Michigan and Ohio federal courts after public health officials linked contaminated lettuce that was supplied to Taco Bell to a parasitic outbreak that's sickened more than 1,600 people in several states.

  • July 17, 2026

    US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine

    The federal government asked the U.S. Court of Federal Claims on Friday to dismiss much of a patent suit against it by Arbutus Biopharma tied to Moderna's COVID-19 vaccine, saying the court couldn't hear the bulk of the case because Arbutus and Moderna reached a multibillion-dollar consent judgment that is subject to appeal.

  • July 17, 2026

    Ex-Hospital Exec Can't Cite Tainted Jury To Ditch Fraud Case

    A former Chicago hospital executive who is fighting extradition to face federal prosecutors' $239 million COVID-19 testing fraud charges cannot seek the same grand jury misconduct-based dismissal his former co-defendants received until he submits himself to the Northern District of Illinois' jurisdiction, a federal judge has ruled.

  • July 17, 2026

    Fed. Circ. Won't Review Reversal In $18M Penile Implant Case

    The full Federal Circuit said Friday that it won't review a panel decision that mostly undid a California federal jury verdict that awarded $18.3 million to International Medical Devices Inc. in a trade secret case about penile implants.

  • July 17, 2026

    Md. Judge Stays Reforms Set To Shrink ACA Coverage Pool

    A Maryland federal judge stayed a set of Affordable Care Act marketplace reforms that were set to take effect Monday, finding several cities and groups representing doctors and small businesses were likely to succeed in their Administrative Procedure Act challenge against them.

  • July 17, 2026

    Drug Buyers' $62M Generic-Pricing Deal Gets Final OK

    A federal judge granted final approval to wholesalers on settlements worth a total of at least $62 million with Glenmark Pharmaceutical Inc., Pfizer Inc. and Pfizer subsidiary Greenstone LLC over claims the companies colluded with others to keep generic drug prices high, according to court orders.

  • July 17, 2026

    Mass. Drug Co. To Pay $4.7M To Resolve Kickback Claims

    A Massachusetts-based pharmaceutical company has agreed to pay $4.7 million to settle allegations that it paid illegal kickbacks to physicians to induce them to buy a drug that treats eye inflammation, the U.S. Department of Justice said Friday.

  • July 17, 2026

    Medical Groups Urge 1st Circ. To Back Vaccine Panel Freeze

    The American Academy of Pediatrics and other public health organizations on Friday defended before the First Circuit a Massachusetts judge's decision to block Health Secretary Robert F. Kennedy Jr.'s vaccine policy committee appointments, countering claims that the judge overreached.

  • July 17, 2026

    DaVita Wins Bid To Decertify 1,300-Member Collective

    A Colorado federal judge dismantled a collective action brought by DaVita nurses and technicians alleging the kidney care giant forced them to work through unpaid meal breaks, finding Friday that the roughly 1,300 workers' vastly different experiences made collective treatment impossible.

  • July 17, 2026

    Taxation With Representation: Freshfields, Slaughter And May

    In this week's Taxation With Representation, Uber Technologies Inc. buys food delivery company Delivery Hero SE, engineering group ABB Ltd. acquires flow technology company Rotork PLC, and Eli Lilly and Co. buys drug developer AtaiBeckley Inc.

  • July 17, 2026

    The Biggest Trade Secret Rulings Of 2026: A Midyear Report

    The Federal Circuit issued two of the year's most consequential trade secret rulings within days of each other, wiping out Insulet's victory in a wearable insulin patch pump case while reopening a software company's path to potentially larger damages in a dispute with Ford Motor Co. Here, Law360 highlights the biggest trade secret decisions so far this year.

  • July 17, 2026

    UK Litigation Roundup: Here's What You Missed In London

    The past week in London has seen Snapchat and Dolby press on with a fresh infringement claim in their ongoing patent battle, The Telegraph face an intellectual property claim by a photo archive, a group of international human rights barristers and chambers sued, and oil business Equinor embroiled in a contract dispute with BP after recently acquiring full ownership in their offshore project. Here, Law360 looks at these and other new claims in the U.K.

  • July 17, 2026

    Commerce Opens Duty Probes Into Chinese Supplements

    The U.S. Department of Commerce is investigating whether certain dietary supplements imported from China are being sold at unfair prices and should be subject to antidumping and countervailing duties, it said Friday.

  • July 16, 2026

    FDA, Drugmakers Urge 5th Circ. To Allow Abortion Pill By Mail

    The U.S. Food and Drug Administration and the makers of the abortion medication mifepristone have urged the Fifth Circuit not to reinstate an in-person dispensing requirement, arguing that doing so would disrupt the government's ongoing review of the drug, "threaten chaos" and defy the U.S. Supreme Court.

  • July 16, 2026

    Pharma Co. Beats Investor Suit Over Prostate Drug Trial

    A Wisconsin federal judge ruled Wednesday that investors of prostate cancer treatment developer Essa Pharma Inc. have not shown they were misled by the company on the efficacy of its lead drug candidate, which was not as effective as an existing treatment for certain cancer patients in a terminated clinical trial.

  • July 16, 2026

    Fed. Circ. Asked Not To Shift Moderna Vax Patent Case To Gov't

    Drugmakers like Novartis, former federal judges, a startup group and others have urged the Federal Circuit to reject calls to shift liability in a COVID-19 vaccine patent suit against Moderna to the federal government, saying that doing so would undermine patent rights.

  • July 16, 2026

    DEA Judge Lays Out Next Steps Following End Of Pot Hearing

    A U.S. Drug Enforcement Administration administrative law judge has laid out upcoming deadlines following the conclusion of hearings on a proposal to move marijuana to Schedule III under the Controlled Substances Act.

  • July 16, 2026

    Senate Democrats Revive Bill To End Federal Marijuana Ban

    Senate Democrats on Thursday once again reintroduced a cannabis legalization bill that would remove the drug entirely from the ambit of the Controlled Substances Act and impose a tax-and-regulate scheme akin to what is currently in place for alcohol and tobacco.

  • July 16, 2026

    Walgreens Sues Mass. Medicaid Program Over Drug Rates

    Walgreens says administrators of the Massachusetts Medicaid program cannot rely on drug prices negotiated with pharmacy benefit managers to determine reimbursement rates, in a challenge to the state's effort to claw back $242,000 in alleged overpayments.

  • July 16, 2026

    Fed. Circ. Vacates $12.7M Copyright Award Against Gov't

    The Federal Circuit on Thursday vacated a $12.7 million copyright award against the federal government over unauthorized copies of software for a project on military health records, holding that the trial judge improperly relied on the project's later cancellation and awarded enhanced damages for willful infringement against the government.

  • July 16, 2026

    Ropes & Gray, Latham Steer $3.8B Eli Lilly Mental Health Deal

    Eli Lilly said Thursday it will acquire New York-based drug developer AtaiBeckley Inc. in a deal valued at up to $3.8 billion, expanding its pipeline of experimental treatments for depression and other mental health disorders.

  • July 16, 2026

    USTR Broadens Exemptions Ahead Of 25% Brazil Tariff

    A 25% tariff on Brazilian goods will begin next week with an expanded exemption list following public comments on the action, U.S. Trade Representative Jamieson Greer announced.

  • July 16, 2026

    Diagnostics Co. Labcorp Settles FCA Claims For $14.5M

    Diagnostics testing company Labcorp will pay $14.5 million to settle False Claims Act allegations that it submitted unnecessary Medicare claims for urine drug tests, the Massachusetts U.S. attorney's office announced.

  • July 15, 2026

    Albertsons Slow To Review Wash. Opioid Sales, Judge Told

    Albertsons conducted few reviews of opioid dispensing by its Washington pharmacies for years after establishing a controlled substances compliance team, according to testimony played on Day 3 of a bench trial in the state's lawsuit accusing the company and its Safeway subsidiary of exacerbating Washington's opioid epidemic.

  • July 15, 2026

    Circuit-By-Circuit Guide To The US Supreme Court's Term

    Federal appeals courts had wide-ranging successes and struggles during the U.S. Supreme Court's recently completed term: One had its best showing in years following its worst showing in years; one felt déjà vu after recently starting to find favor with the justices; and one saw its reputation for independence occupy a rare role in the Supreme Court spotlight.

Expert Analysis

  • Series

    The Biz Court Digest: Dispatches From Utah's Newest Court

    Author Photo

    While a robust body of law hasn't yet developed since the Utah Business and Chancery Court's founding in October 2024, the number of cases filed there has recently picked up, and its existence illustrates Utah's desire to be top of mind for businesses across the country, says Evan Strassberg at Michael Best.

  • Checking In On Biologics-Related Patent Review Trends

    Author Photo

    Comprehensive analysis of Patent Trial and Appeal Board data since the PTAB's creation indicates that while inter partes review and post-grant review are potent weapons for challenging biologics-related patents, recent policy changes may reduce their effectiveness, say attorneys at Steptoe.

  • 4 Quick Emotional Resets For Lawyers With Conflict Fatigue

    Author Photo

    Though the emotional wear and tear of legal work can trap attorneys in conflict fatigue — leaving them unable to shake off tense interactions or return to a calm baseline — simple therapeutic techniques for resetting the nervous system can help break the cycle, says Chantel Cohen at CWC Coaching & Therapy.

  • Rescheduling Cannabis Marks New Tax Era For Operators

    Author Photo

    As the attorney general takes steps to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, operators and advisers should prepare by considering the significant changes this will bring from tax, state, industry and market perspectives, says Michael Harlow at CohnReznick.

  • Navigating Trade Secret Exceptions In Noncompete Bans

    Author Photo

    Recent and ongoing developments in the noncompete landscape, including a potential decision from the Tenth Circuit in Edwards Lifesciences v. Thompson, could offer tools for employers to bring noncompete agreements within trade secret exceptions amid an era of heightened employee mobility, say attorneys at Sullivan & Cromwell.

  • Series

    Playing Tennis Makes Me A Better Lawyer

    Author Photo

    An instinct to turn pain into purpose meant frequent trips to the tennis court, where learning to move ahead one point at a time was a lesson that also applied to the steep learning curve of patent prosecution law, says Daniel Henry at Marshall Gerstein.

  • Expect Major Shifts In Patent And Trademark Policy This Year

    Author Photo

    New leadership and initiatives promise to bring consequential changes to the U.S. Patent and Trademark Office's practices in 2026, likely favoring patent allowance and issuance, as well as streamlining trademark processes, say attorneys at Knobbe Martens.

  • Class Actions At The Circuit Courts: January Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five rulings from October and November, and identifies practice tips from cases involving consumer fraud, oil and gas leases, toxic torts, and wage and hour issues.

  • Series

    Judges On AI: How Judicial Use Informs Guardrails

    Author Photo

    U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.

  • What US Cos. Must Know To Comply With Italy's AI Law

    Author Photo

    Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.

  • Ag Bill Wording Presents Existential Threat To Hemp Industry

    Author Photo

    A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.